PURPOSE: To provide a summary of the outcomes of two working conferences organized by the Centers for Disease Control and Prevention (CDC), to develop recommendations for practical, sustainable mechanisms to make quality control (QC) materials available to the genetic testing community. METHODS: Participants were selected to include experts in genetic testing and molecular diagnostics from professional organizations, government agencies, industry, laboratories, academic institutions, cell repositories, and proficiency testing (PT)/external Quality Assessment (EQA) programs. Current efforts to develop QC materials for genetic tests were reviewed; key issues and areas of need were identified; and workgroups were formed to address each area of need and to formulate recommendations and next steps. RESULTS: Recommendations were developed toward establishing a sustainable process to improve the availability of appropriate QC materials for genetic testing, with an emphasis on molecular genetic testing as an initial step. CONCLUSIONS: Improving the availability of appropriate QC materials is of critical importance for assuring the quality of genetic testing, enhancing performance evaluation and PT/EQA programs, and facilitating new test development. To meet the needs of the rapidly expanding capacity of genetic testing in clinical and public health settings, a comprehensive, coordinated program should be developed. A Genetic Testing Quality Control Materials Program has therefore been established by CDC in March 2005 to serve these needs.
PURPOSE: To provide a summary of the outcomes of two working conferences organized by the Centers for Disease Control and Prevention (CDC), to develop recommendations for practical, sustainable mechanisms to make quality control (QC) materials available to the genetic testing community. METHODS:Participants were selected to include experts in genetic testing and molecular diagnostics from professional organizations, government agencies, industry, laboratories, academic institutions, cell repositories, and proficiency testing (PT)/external Quality Assessment (EQA) programs. Current efforts to develop QC materials for genetic tests were reviewed; key issues and areas of need were identified; and workgroups were formed to address each area of need and to formulate recommendations and next steps. RESULTS: Recommendations were developed toward establishing a sustainable process to improve the availability of appropriate QC materials for genetic testing, with an emphasis on molecular genetic testing as an initial step. CONCLUSIONS: Improving the availability of appropriate QC materials is of critical importance for assuring the quality of genetic testing, enhancing performance evaluation and PT/EQA programs, and facilitating new test development. To meet the needs of the rapidly expanding capacity of genetic testing in clinical and public health settings, a comprehensive, coordinated program should be developed. A Genetic Testing Quality Control Materials Program has therefore been established by CDC in March 2005 to serve these needs.
Authors: Sarah Berwouts; Katrina Fanning; Michael A Morris; David E Barton; Elisabeth Dequeker Journal: Eur J Hum Genet Date: 2012-06-27 Impact factor: 4.246
Authors: Victoria M Pratt; Barbara Zehnbauer; Jean Amos Wilson; Ruth Baak; Nikolina Babic; Maria Bettinotti; Arlene Buller; Ken Butz; Matthew Campbell; Chris Civalier; Abdalla El-Badry; Daniel H Farkas; Elaine Lyon; Saptarshi Mandal; Jason McKinney; Kasinathan Muralidharan; LeAnne Noll; Tara Sander; Junaid Shabbeer; Chingying Smith; Milhan Telatar; Lorraine Toji; Anand Vairavan; Carlos Vance; Karen E Weck; Alan H B Wu; Kiang-Teck J Yeo; Markus Zeller; Lisa Kalman Journal: J Mol Diagn Date: 2010-10-01 Impact factor: 5.568
Authors: Victoria M Pratt; Michele Caggana; Christina Bridges; Arlene M Buller; Lisa DiAntonio; W Edward Highsmith; Leonard M Holtegaard; Kasinathan Muralidharan; Elizabeth M Rohlfs; Jack Tarleton; Lorraine Toji; Shannon D Barker; Lisa V Kalman Journal: J Mol Diagn Date: 2009-04-09 Impact factor: 5.568
Authors: Maria P Bettinotti; Deborah Ferriola; Jamie L Duke; Timothy L Mosbruger; Nikolaos Tairis; Lawrence Jennings; Lisa V Kalman; Dimitri Monos Journal: J Mol Diagn Date: 2018-06-26 Impact factor: 5.568
Authors: Shannon D Barker; Sherri Bale; Jessica Booker; Arlene Buller; Soma Das; Kenneth Friedman; Andrew K Godwin; Wayne W Grody; Edward Highsmith; Jeffery A Kant; Elaine Lyon; Rong Mao; Kristin G Monaghan; Deborah A Payne; Victoria M Pratt; Iris Schrijver; Antony E Shrimpton; Elaine Spector; Milhan Telatar; Lorraine Toji; Karen Weck; Barbara Zehnbauer; Lisa V Kalman Journal: J Mol Diagn Date: 2009-09-18 Impact factor: 5.568
Authors: Lisa Kalman; Jean Amos Wilson; Arlene Buller; John Dixon; Lisa Edelmann; Louis Geller; William Edward Highsmith; Leonard Holtegaard; Ruth Kornreich; Elizabeth M Rohlfs; Toby L Payeur; Tina Sellers; Lorraine Toji; Kasinathan Muralidharan Journal: J Mol Diagn Date: 2009-10-08 Impact factor: 5.568
Authors: Lisa V Kalman; Jack C Tarleton; Alan K Percy; Swaroop Aradhya; Sherri Bale; Shannon D Barker; Pinar Bayrak-Toydemir; Christina Bridges; Arlene M Buller-Burckle; Soma Das; Ramaswamy K Iyer; Timothy D Vo; Val V Zvereff; Lorraine H Toji Journal: J Mol Diagn Date: 2014-02-07 Impact factor: 5.568
Authors: Lisa Kalman; Jay Leonard; Norman Gerry; Jack Tarleton; Christina Bridges; Julie M Gastier-Foster; Robert E Pyatt; Eileen Stonerock; Monique A Johnson; C Sue Richards; Iris Schrijver; Tianhui Ma; Vanessa Rangel Miller; Yetsa Adadevoh; Pat Furlong; Christine Beiswanger; Lorraine Toji Journal: J Mol Diagn Date: 2011-03 Impact factor: 5.568
Authors: Lisa Kalman; Jack Tarleton; Monica Hitch; Madhuri Hegde; Nick Hjelm; Elizabeth Berry-Kravis; Lili Zhou; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley; Lorraine Toji Journal: J Mol Diagn Date: 2013-05-13 Impact factor: 5.568